Skip to content

IO Vancomycin Spine

Intraosseous vs. Intravenous Vancomycin Administration in Spine Surgery

Status
Not yet recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06748144
Enrollment
30
Registered
2024-12-27
Start date
2026-05-01
Completion date
2030-04-01
Last updated
2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Fusion Surgery

Brief summary

The goal of this research is to learn if injecting the antibiotic vancomycin directly into the bone marrow (intraosseous) or IO) during a lumbar (spinal) fusion surgery, is as effective or better than the standard method of giving it vancomycin through a vein (intravenous) or IV) during lumbar fusion surgery.

Interventions

The intervention is specific to the method of administration that will be used when giving the dose of antibiotic vancomycin which is done to prevent infection following surgery.

This is the standard method of giving the antibiotic vancomycin to patients undergoing surgery across many specialties in order to prevent infection.

Sponsors

The Methodist Hospital Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient is undergoing open posterior instrumented spinal fusion (PSIF) or transforaminal lumbar interbody fusion (TLIF) * Patient is able to give informed consent to participate on the study. LAR consents will not be utilized for this study * Age Range \>18

Exclusion criteria

* Previous spine surgery if surgeon deems it will affect the study * BMI \> 40 * Contraindication to receiving vancomycin, cefepime, ancef, or other standard of care pre-operative antibiotic (allergy, medical issue, etc). * Inability to administer the IO infusion * Refusal to participate * Diabetes as defined as uncontrolled A1C \> 7.5 and eGFR \<59 * Immunocompromised or immunosuppressed patients (HIV, Hep C, ESRD, dialysis, transplant, chemo/radiation treatment in last 6 months, medications) * No vulnerable populations

Design outcomes

Primary

MeasureTime frameDescription
Change in Level of Systemic Vancomycin ConcentrationStart of skin incision during surgery, Start of closure of skin incision during surgeryThe level of vancomycin concentration will be assessed via a blood draw by the anesthesiologist staff.
Level of Vancomycin Concentration in BoneDuring surgeryBony tissue samples (Superior Articular Process, Inferior Articular Process, and Lamina) will be taken during surgery to assess levels of vancomycin concentration in the bone.
Level of Vancomycin Concentration in Soft TissueDuring surgerySoft tissue samples (Multifidus muscle, Fat) will be taken during surgery to assess levels of vancomycin concentration in the tissue.

Secondary

MeasureTime frameDescription
Post-Operative Complication Rates30 Days Post Surgery, 90 Days Post SurgeryParticipant's charts will be reviewed postoperatively to determine if there were any adverse local/systemic reactions and/or complications following the surgery.

Countries

United States

Contacts

CONTACTEmily Vidal
evidal@houstonmethodist.org346-238-4675

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026